Richard Eberly

President and CEO at Chembio Diagnostics - Medford, NY, US

Richard Eberly's Colleagues at Chembio Diagnostics
Chuck Caso

Vice President, Sales & Marketing

Contact Chuck Caso

Melissa Gallagher

Director - Reporting, Financial Planning & Analysis

Contact Melissa Gallagher

Sandy Speer

Senior Director Client Services

Contact Sandy Speer

Steven Hu

Director of R & D

Contact Steven Hu

Jillian Cappello

Manager Regulatory Affairs

Contact Jillian Cappello

Bill Schneider

Sr. Manager, Manufacturing Process Improvement Projects

Contact Bill Schneider

Corinne MBA

Human Resources Specialist

Contact Corinne MBA

View All Richard Eberly's Colleagues
Richard Eberly's Contact Details
HQ
631-924-1135
Location
Company
Chembio Diagnostics
Richard Eberly's Company Details
Chembio Diagnostics logo, Chembio Diagnostics contact details

Chembio Diagnostics

Medford, NY, US • 100 - 249 Employees
Medical Equipment

About Chembio Diagnostics:Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.About the DPP Rapid Test Platform:Chembio's proprietary DPP® technology platform provides high-quality, rapid diagnostic results in 15 to 20 minutes using a small drop of blood from the fingertip or alternative samples. Through advanced multiplexing, the DPP platform can detect up to eight, distinct test results from a single patient sample, delivering greater clinical value than other rapid tests. For certain applications, Chembio's easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzer then reports accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on-site. Objective results produced by the DPP Micro Reader reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.Chembio's portfolio of DPP-based point-of-care tests with FDA regulatory approvals include the DPP HIV-Syphilis System (PMA approved), DPP HIV 1/2 Assay (PMA approved and CLIA waived), DPP Zika IgM System (510(k)), and DPP Ebola Antigen System (EUA). Additionally, DPP-based tests have received regulatory approvals from the World Health Organization, CE-Mark, Agência Nacional de Vigilância Sanitária (ANVISA), and other global organizations.

B2B Biotechnology Healthcare Medical Devices Medical Diagnostics Pharmaceuticals Medical Equipment Medical and Hospital Equipment Research Development Business Services
Details about Chembio Diagnostics
Frequently Asked Questions about Richard Eberly
Richard Eberly currently works for Chembio Diagnostic Systems, Inc..
Richard Eberly's role at Chembio Diagnostic Systems, Inc. is President and CEO.
Richard Eberly's email address is ***@chembio.com. To view Richard Eberly's full email address, please signup to ConnectPlex.
Richard Eberly works in the Medical Devices industry.
Richard Eberly's colleagues at Chembio Diagnostics are Chuck Caso, Melissa Gallagher, Sandy Speer, Steven Hu, Jillian Cappello, Bill Schneider, Corinne MBA and others.
Richard Eberly's phone number is 631-924-1135
See more information about Richard Eberly